Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; Multi-                              ( print page 49389)                            Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01; R34).                    

*Date:*                         November 7, 2017.                    

*Time:*                         1:00 p.m. to 3:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).                    

*Contact Person:*                         Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892-9550, 301-827-5819,                         *gm145a@nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; Limited Competition—Cohort Studies of HIV/AIDS and Substance Abuse (U01).                    

*Date:*                         November 7, 2017.                    

*Time:*                         2:00 p.m. to 3:30 p.m.                    

*Agenda:*                         To review and evaluate cooperative agreement applications.                    

*Place:*                         National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).                    

*Contact Person:*                         Hiromi Ono, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820,                         *hiromi.ono@nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01).                    

*Date:*                         November 10, 2017.                    

*Time:*                         12:00 p.m. to 3:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).                    

*Contact Person:*                         Hiromi Ono, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820,                         *hiromi.ono@nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; Wearable to Track Recovery and Relapse Factors for People w/Addiction (R43, R44).                    

*Date:*                         November 21, 2017.                    

*Time:*                         1:00 p.m. to 4:30 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).                    

*Contact Person:*                         Julia Berzhanskaya, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892, 301-827-5840,                         *julia.berzhanskaya@nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; NIDA Research Education Program for Clinical Researchers and Clinicians (R25).                    

*Date:*                         December 4, 2017.                    

*Time:*                         12:00 p.m. to 3:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).                    

*Contact Person:*                         Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892-9550, 301-827-5819,                         *gm145a@nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; Nasal Delivery of CNS Therapeutics (R41, R42, R43, R44).                    

*Date:*                         December 5, 2017.                    

*Time:*                         1:00 p.m. to 4:30 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).                    

*Contact Person:*                         Julia Berzhanskaya, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892, 301-827-5840,                         *julia.berzhanskaya@nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; Conference Grant Review (R13).                    

*Date:*                         December 6, 2017.                    

*Time:*                         1:00 p.m. to 4:30 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).                    

*Contact Person:*                         Shang-Yi Anne Tsai, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892, 301-827-5842,                         *shangyi.tsai@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: October 19, 2017.

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017-23128 Filed 10-24-17; 8:45 am]

 BILLING CODE 4140-01-P